Samuraciclib
- Generic Name
- Samuraciclib
- Drug Type
- Small Molecule
- Chemical Formula
- C22H30N6O
- CAS Number
- 1805833-75-3
- Unique Ingredient Identifier
- 46D4HS9ODA
- Background
Samuraciclib is under investigation in clinical trial NCT03363893 (Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies).
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 11
- Registration Number
- NCT06125522
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸UCHealth Harmony, Fort Collins, Colorado, United States
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
- Conditions
- Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Carrick Therapeutics Limited
- Target Recruit Count
- 60
- Registration Number
- NCT05963984
- Locations
- 🇺🇸
Ocala Oncology Center PL DBA Florida Cancer Affiliates, Ocala, Florida, United States
🇺🇸Mfsmc-Hjwci, Baltimore, Maryland, United States
🇺🇸Saint Luke's Cancer Institute, Kansas City, Missouri, United States
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
- Conditions
- Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Carrick Therapeutics Limited
- Target Recruit Count
- 48
- Registration Number
- NCT05963997
- Locations
- 🇺🇸
Site 38 - Northwestern University, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States
🇺🇸Site 42 - Dana-Farber Cancer Institute, EDDC, Boston, Massachusetts, United States
🇺🇸Site 35 - Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, United States
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- Conditions
- Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 316
- Registration Number
- NCT04802759
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇮🇱Rabin MC, Petach Tikva, Israel
🇮🇱Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.